Xenitra (ASX:XEN) announced the 100% acquisition of Hong Kong Fukang Trading.
The transaction, valued at approximately ¥469,243, marks a milestone for the Sydney-based fast-moving consumer goods and nutraceuticals specialist.
By absorbing Fukang's entire share capital and physical assets, Xenitra effectively operationalises its over-the-counter medicines business within the competitive Chinese and Hong Kong markets.
The acquisition is particularly valuable due to the inclusion of the Hong Kong Pharmaceutical Licence PW-2024-00189, which provides the critical regulatory framework required for cross-border pharmaceutical distribution.
Beyond the licence, Xenitra gains immediate access to a robust logistics infrastructure, including warehouse service deposits with the Hong Kong Kanghong Pharmaceutical Group and established eCommerce shopfronts on JD.com.
The assets, combined with existing inventory and a Class 35 trademark registration, allow the company to bypass traditional market-entry barriers.
Chairman Anthony Noble highlighted that the integration of Fukang’s experienced local team and extensive customer databases will facilitate a seamless expansion of Xenitra’s product range.
Following the company’s initial wholesale authorisation in late 2025, this move is expected to drive meaningful growth by leveraging established distribution channels across B2B wholesale and retail platforms.
At the time of reporting, Xenitra’s share price was $0.0030.